Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Manufacture Business Practice, Biosimilars, Trends & Forecasts

The Big Break for Biosimilars?

Back in April 2006, the first biosimilar in the European Union received marketing authorization – Omnitrope, developed by Sandoz as a biosimilar to Pfizer’s Genotropin (somatropin). At the time, there was no sign of a biosimilars pathway in the US, but everyone anticipated that such products would eventually jump the Atlantic. ‘Eventually’ was nearly nine years later when on March 6, 2015, the FDA officially approved the first US biosimilar – Zarxio (filgrastim-sndz) from Sandoz (1), which is approved for the same indications as Amgen’s Neupogen (filgrastim). Is the US biosimilars market now open for business and ready to start churning out a whole raft of new products? That really depends on who you speak to...

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Stephanie Sutton

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent seven years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register